Recruiting nowN/AAges 18 Years and up
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle · NCT04224064 on ClinicalTrials.gov ↗
Conditions studied
LiposarcomaAtypical Lipomatous Tumor
What it tests
- Blood samplingdiagnostic_test
Where it's running1 site
1 international site
- Recruiting now
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, France 34298
- Marc YCHOU, MD, PhD(contact)+33467613102[email protected]
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria for LPS patients cohort: Men/women older than 18 years old, Surgery for : * Localized WD-LPS and DD-LPS, and/or * WD-LPS or DD-LPS local relapse, and/or * WD-LPS or DD-LPS distant relapse and/or * Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent Inclusion Criteria for healthy subjects cohort: Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort Exclusion Criteria: Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma. Pregnancy and/or feeding
Updated 2025-02-12 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.